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Could BRAF Mutations in Melanocytic 
Lesions Arise from DNA Damage 
Induced by Ultraviolet Radiation?
Nancy E. Thomas1,2, Marianne Berwick3 and Marila Cordeiro-Stone1,4
Although BRAF V600 mutations in melanocytic tumors are not UV-
signature mutations, it is plausible that they could still arise from error-
prone replication of UV-damaged DNA. We propose a mechanism for 
their origin, taking into consideration melanocytic-specifi c BRAF tan-
dem mutations, nearby potential pyrimidine dimer sites, the properties 
of specialized DNA polymerases, and biological selection.
Journal of Investigative Dermatology (2006) 126, 1693–1696. doi:10.1038/sj.jid.5700458
Shortly after BRAF mutations were dis-
covered and found to be present in 
about 60% of melanomas (Davies et 
al., 2002), their presence was reported 
in 20%–80% of melanocytic nevi in a 
variety of studies (Kumar et al., 2004; 
Pollock et al., 2003; Yazdi et al., 2003). 
Now, Lassacher et al. (2006, this issue) 
have extended our knowledge in this 
area by reporting their finding that the 
t1796a mutation at codon 599 (V599) 
of BRAF is also common in biopsies 
of lentigines from patients who have 
received psoralen plus UVA (PUVA) 
treatment for psoriasis. The authors 
concluded that PUVA lentigines might 
be precursors of cutaneous malignant 
melanomas and that the BRAF muta-
tions could be related to the molecular 
and cellular effects of PUVA. Previous 
studies in TP53 of basal-cell carcino-
mas (Seidl et al., 2001), INK4A/ARF of 
squamous-cell carcinomas (Kreimer-
Erlacher et al., 2003), and TP53 and 
HRAS of keratoses (Wolf et al., 2004) 
from PUVA-treated psoriasis patients 
disclosed that the majority of the muta-
tions in the analyzed genes were C>T or 
CC>TT transitions at dipyrimidine sites, 
which are recognized as UV-signature 
mutations. The etiology of BRAF muta-
tions in melanocytic lesions, however, 
is far from clear. The t1796a BRAF muta-
tion is embedded in a sequence (5′GTG) 
where psoralen binding could possibly 
induce the T>A transversion, although 
mono-addition and cross-linking of 
psoralens occur preferentially at 5′ATA 
and 5′TA (Esposito et al., 1988). PUVA 
treatment may increase melanoma risk 
(Stern, 2001), but study of PUVA is con-
founded by the fact that patients treated 
with PUVA also typically have received 
multiple psoriasis treatments, including 
UVB, tar, and/or immunosuppressants, 
such as cyclosporine and methotrexate. 
In this Commentary, we would like to 
explore the possibility that BRAF muta-
tions detected in melanocytic lesions 
from areas of the skin that are prone to 
sunburns could arise from UVB-induced 
DNA photoproducts, such as cyclobu-
tane pyrimidine dimers (CPDs) and 
[6-4] pyrimidine-pyrimidone adducts 
([6-4]PPs). (Note: The numbering of 
BRAF codon V599E (t1796a) reported 
by Lassacher et al. is the same as in 
the original article on BRAF mutations 
in melanomas by Davies et al. (2002). 
Later in this Commentary, we present 
the numbering according to the cor-
rection by which the National Cancer 
Institute gene bank renamed the V599E 
(t1796a) mutation as V600E (t1799a); 
accession number NM_004333.2.)
Melanoma risk is complex, but con-
siderable roles for intermittent sun 
exposure and sunburn history have 
been identified in epidemiologic stud-
ies (Gandini et al., 2005b). Number 
of common nevi is also an important 
risk factor for melanoma (Gandini et 
al., 2005a). The pathogenic effects of 
sun exposure could involve the geno-
toxic, mitogenic, or immunosuppres-
sive responses to the damage induced 
in the skin by UV. Controversial is whe-
ther the UVB or the UVA component 
of solar radiation is more important in 
melanoma development (De Fabo et 
al., 2004; Wang et al., 2001). UVB rep-
resents only a small portion of the solar 
radiation reaching the earth’s surface 
(<5%) but is quite efficient in inducing 
promutagenic CPDs and [6-4]PPs at 
dipyrimidine sites. UVA damages DNA 
primarily through the generation of 
reactive oxygen species and formation 
of 8-oxo-7,8-dihydro-2′-deoxyguano-
sine; accordingly, G>T transversions 
are the major mutations induced by 
UVA in mammalian cells (Besaratinia 
and Pfeifer, 2005). Several possible UV 
targets have been recognized, includ-
ing the INK4A, TP53, and RAS genes, 
which can have mutations in melano-
mas; however, BRAF, which is often 
mutated in nevi and melanomas, may 
also deserve serious consideration as a 
UV target.
Suggestive of a role for UV in the for-
mation of BRAF mutations are findings 
that these mutations are more common 
in melanomas arising on intermittently 
than rarely sun-exposed anatomic sites 
(Edwards et al., 2004; Maldonado et 
al., 2003). Edwards et al. (2004) have 
discussed the possible contributions to 
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Do these melanocytic-
specifi c BRAF tandem 
mutations provide a 
mechanistic clue to 
genotoxic damage in 
melanomas?
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BRAF mutations of UV-induced DNA 
lesions other than CPDs and [6-4]PPs, 
including minor photoproducts and 
oxidative damage. Additional evidence 
that BRAF mutations might arise from 
UV exposure are findings that mela-
nocytic lesions often include tandem 
BRAF mutations (Thomas et al., 2004), 
which are rarely found in other non-
melanocytic tumors harboring BRAF 
mutations (such as colon, thyroid, ova-
rian, and lung cancer) (Salvatore et al., 
2004; Samowitz et al., 2005; Sieben 
et al., 2004). Only one V600 tandem 
mutation has been reported in a non-
melanocytic lesion (a cholangiocarci-
noma) (Tannapfel et al., 2003), whereas 
approximately 25% of BRAF mutations 
in primary invasive melanomas are 
tandem mutations (Maldonado et al., 
2003; Thomas et al., 2004). Do these 
melanocytic-specific BRAF tandem 
mutations provide a mechanistic clue 
to genotoxic damage in melanomas?
The most common BRAF muta-
tion found in melanocytic nevi and 
melanomas, the t1799a substitution 
— that is, the V600E mutation — is 
not at a dipyrimidine site, and, thus, 
it is not generally viewed as resulting 
from error-prone replication of UVB-
 damaged DNA. However, this possibil-
ity cannot be ruled out when one takes 
into consideration the known proper-
ties of specialized DNA polymerases. 
These enzymes catalyze nucleotide 
poly merization across template DNA 
lesions that stall the progression of 
replication forks. The BRAF sequence 
surrounding codon 600 includes sev-
eral dipyrimidine sites where photo-
products could be formed by UVB 
absorption (Figure 1). As reviewed 
recently by Pfeifer et al. (2005), CPDs 
(rather than [6-4]PPs or other lesions) 
are associated with the great majority 
of UVB-induced mutations, and cyto-
sine deamination could be responsible 
for most of the C>T substitutions. 
DNA polymerase η (pol η) repre-
sents an important safeguard against 
the mutagenic effects of CPDs; although 
these lesions are strong blocks to the 
replicative polymerases, the active site 
of pol η is flexible enough to accommo-
date the dimers, “read” their sequence 
composition, and replicate beyond the 
photoproduct with an error rate of 10–2 
to 10–3 (Johnson et al., 2000). This means 
that pol η is an error-prone enzyme 
that makes a mistake for every 100 to 
1,000 nucleotide incorporation events 
(including during replication of undam-
aged DNA) but allows human cells to 
complete replication in the presence of 
UV-induced DNA damage and survive 
with a low mutagenic burden. It is still 
not understood how pol η gains access 
to the stalled replication fork and, soon 
after completing synthesis across the 
CPD, hands the growing nascent DNA 
back to DNA polymerase δ (pol δ). 
Primer-extension studies with purified 
enzymes suggested that the processiv-
ity of pol η across the CPD and flanking 
bases is higher than on the undamaged 
sequence and influences the switch-
ing between pol η and pol δ before and 
after the dimer (McCulloch et al., 2004a; 
McCulloch et al., 2004b); this evidence 
implies that pol η could get access to the 
nascent DNA at the –1 position relative 
to the CPD. 
In the diagrams in Figure 2, we con-
sider the possibility of accurate (Figure 
2a) or inaccurate (Figure 2b) polymeriza-
tion across the nucleotide just preceding 
a CPD at the 1800–1801 dipyrimidines. 
Also considered in Figure 2b is the evi-
dence that pol η is not adept at extend-
ing a mismatched primer (Masutani et 
al., 2000). DNA polymerase ζ (pol ζ), 
however, is more efficient at extending 
from base mispairs created by another 
Figure 1. Single and tandem mutations in codon 600 of BRAF in melanocytic lesions. Nucleotide 
sequence surrounding V600 in wild-type BRAF is illustrated to show dipyrimidine sites where UV-
induced DNA photoproducts could be formed (asterisks); these positions are color-coded to indicate the 
relative probability of cyclobutane pyrimidine dimer (CPD) formation as high (red), intermediate (green), 
or low (blue). Both CPDs and [6-4] pyrimidine-pyrimidone adducts ([6-4]PPs) can be formed at 5′TC 
sites at approximately the same frequency; because of the higher rate of removal of [6-4]PPs than CPDs 
by error-free nucleotide excision repair, it is more likely that a CPD at the 1800–1801 position might 
influence the fixation of the single or tandem BRAF mutations listed in this figure (see text for details).
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polymerase (reviewed by Prakash and 
Prakash, 2002), a characteristic that 
appears to underlie the finding that 
UV-induced mutagenesis is strongly 
dependent on pol ζ (Gibbs et al., 1998). 
Therefore, it is the encounter of a tem-
plate CPD by the replication machinery 
that would set the stage for the switch 
of pol δ for pol η, followed by accurate 
translesion synthesis before handing 
back of the growing strand to pol δ one 
or two nucleotides beyond the dimer 
(Figure 2a). If the 3′C at the dimer were 
to undergo deamination, then accurate 
translesion synthesis by pol η would 
result in a silent C>T substitution at the 
1800 position (Figure 2a). 
Figure 2b envisions the possibility 
of the error-prone pol η inserting an A 
at the 1799 position and this mispair-
ing causing it to dissociate from the 
growing strand; then, elongation of the 
mispaired primer by pol ζ would lead 
to the t1799a transversion mutation, 
or the tg1799–1800aa tandem muta-
tion when combined with deamination 
at the dimer. Induction of the V600D 
tandem mutation (Figure 1) is more dif-
ficult to explain; it would require pol ζ 
to extend the mispair introduced by pol 
η and make another one of its own at 
position 1800. Finally, acquisition of the 
tandem mutations leading to V600R or 
V600K could possibly be influenced by 
a CPD at the 1797–1798 dipyrimidines. 
Even though CPDs are formed at very 
low frequency at 5′CT, a C>T transition 
facilitated by misincorporation by pol η 
at the +1 position could explain these 
tandem mutations.
In closing, it is important to recognize 
that the explanations offered above for 
how common BRAF mutations could 
be linked to the presence of nearby pyri-
midine dimers require the convergence 
of several rare events. Hence, if they do 
occur as predicted, the common find-
ing of these mutations in BRAF, but 
not in other gene targets, might reflect 
a powerful biological selection for 
mutations at codon 600; this muta-
tion activates the BRAF oncogene, 
and expression of the active oncogene 
stimulates mitogenic signaling in mela-
nocytes at least briefly (Michaloglou et 
al., 2005). Theoretically, repeated blasts 
of intense sun exposure, similar to that 
resulting in sunburn during vacation, 
might lead to the accumulation of mul-
tiple rare events. However, the current 
state of knowledge makes it impossible 
to determine with certainty whether 
UV is involved in the induction of 
BRAF mutations and, if it is, whether 
a
b
Figure 2. Modeling the acquisition of codon 600 BRAF somatic mutations on the basis of error-prone 
translesion synthesis of a UVB-induced CPD. Polymerase η (pol η) is a specialized DNA polymerase 
that contributes to the extension of nascent DNA strands when the replicative polymerases (for example, 
pol δ) are blocked at CPDs. (a) Pol η reduces the probability of UV-induced mutagenesis by catalyzing 
translesion synthesis accurately in more than 99% of CPDs on template DNA. Deamination of cytosines 
to uracil before replication could result in the C:G>T:A transition at the nucleotide position 1800; this 
substitution, however, would be a codon 600 silent mutation, as both GTG and GTA code for valine. 
(b) Mutation fixation across a UV-induced CPD may involve the participation of more than one 
polymerase and is strongly dependent on another specialized DNA polymerase, pol ζ. In the scenario 
depicted in this diagram, pol δ is blocked by the dimer and its exonucleolytic activity removes the last 
incorporated nucleotide before pol η gets access to the stalled replication fork (see text for details). 
With an overall fidelity of 10–2 to 10–3 (even on undamaged templates), pol η could introduce the wrong 
nucleotide before dissociating from the primer template, as this enzyme cannot extend a mismatched 
primer. Pol ζ, however, can carry out such extension quite well. This combination of circumstances 
could lead to the fixation of the t1799a mutation. Deamination at the 3′C of the dimer could lead to the 
tg1799–1800aa tandem mutation. NER, nucleotide excision repair.
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UVB or UVA is the culprit. Whereas 
UVB is a better mutagen, more UVA 
reaches the skin and penetrates deeper. 
UVA can induce CPDs at high doses 
(Pfeifer et al., 2005), although oxida-
tive damage predominates. In addition, 
melanin might contribute to production 
of somatic mutations through incom-
pletely understood photosensitization 
and/or pro-oxidant effects (Meyskens 
et al., 2004; Samokhvalov et al., 2005). 
Further epidemiologic and basic-
science studies will be necessary to 
unravel the contribution that UVA or 
UVB might make in the production of 
BRAF mutations.
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